Khiron Life Sciences Corp.

  • instagram
  • LinkedIn
language
English Español Português Deutsch

A GLOBAL MEDICAL CANNABIS COMPANY

IMPROVING THE QUALITY OF PEOPLES' LIVES

TSXV: KHRN | OTCQX: KHRNF | FRANKFURT: A2JMZC

6
Countries:
 SELLING IN COLOMBIA, PERU, GERMANY, UK, BRAZIL AND TARGETING MEXICO FOR 2022
>50,000
Medical cannabis prescriptions filled year-to-date
>50%
MEDICAL CANNABIS REVENUES GENERATED IN EUROPE IN 01 2022
>70%
Gross margin on medical cannabis sales in 2021
>60%
Retention Rate AT KHIRON'S ZERENIA CLINIC PATIENTS GLOBALLY
>85%
MEDICAL CANNABIS SALES THROUGH INSURANCE IN COLOMBIA

Latest
Presentations

Investor Presentation
INVESTOR PRESENTATION

Recent Event

6th Annual CG Cannabis Conference

View Event View All

Khiron at Benzinga Cannabis Insider

Patients Stories

AWT Mystery Interview #10 Reveal $KHRNF Khiron Life Sciences CEO Alvaro F Torres Co-Founder & CEO

Vicente Fox on BNN Bloomberg

ATB 9th Annual Institutional Investor Conference

OUR
BUSINESS UNITS

khiron
Health Services
khiron
Med

GLOBAL
EXPANSION

Khiron is well-positioned to take advantage of the emerging global cannabis opportunity.

OUR
PRODUCTION FACILITY

Cultivation: Upwards 0f 9 tonnes of dry flower. Fully licensed for commercial THC and CBD cultivation, extraction & sales in Colombia.

  • Total area of 20 Ha. Current cultivation area of 80,000 sq. ft.
  • ~1 MW Solar Park with capacity to reduce energy consumption by 40%

Our
Laboratory

  • State-of-the-art, 14,000 sq.ft. GMP-compliant post-harvest facility in Doima, Colombia (157 km. West of Bogota)
  • Extraction: Up to 3 tonnes of full-spectrum extract, with capacity to expand within the building

Leadership

KHIRON LIFE SCIENCES is led by a multidisciplinary and multicultural team with a unique understanding of various industries across Latin America and Europe

View Management Team View Board of Directors

Investor
Contact

Paola Ricardo

T: 1 (647) 556-5750
investors@khiron.ca

Have a business-related question about KHRN? Or just general inquiries? Send us a message and we'll be happy to help.

Contact Us

Investor Email Alerts